Dr. Alexander Kretschmer on clinical interpretation of the ExoDx Prostate test

April 29, 2021
Urology Times staff

Dr. Alexander Kretschmer, MD, discusses the clinical interpretation and value of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result.

Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.